Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 3/20 | 0.37 |
| ▸ | NOS1 | P29475 | 3/20 | 0.31 |
| ▸ | NOS2 | P35228 | 3/20 | 0.31 |
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3734646 | 0.82 | CYP3A4 (0.37) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL3738574 | 0.82 | CYP3A4 (0.37) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL25030407 | 0.82 | CYP3A4 (0.37) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL33525707 | 0.79 | CYP3A4 (0.45) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL5376874 | 0.78 | MEN1 (0.33) | NOS1NOS2NOS3SLC6A2KCNH2 | |
| SCHEMBL31291962 | 0.77 | CYP3A4 (0.48) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL15114594 | 0.77 | CYP3A4 (0.44) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL5390425 | 0.76 | DPP4 (0.42) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL14932741 | 0.73 | CYP3A4 (0.44) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL4626256 | 0.72 | DPP4 (0.42) | CYP3A4TSHRTDP1MAPTAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312218-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB CO. (US) | 2007-12-25 | — | — | US | claimed |
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | HAN WEI | 2007-05-03 | — | — | US | claimed |
| US-20050096309-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-05 | — | — | US | claimed |
| US-7312218-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB CO. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | HAN WEI | 2007-05-03 | — | — | US | disclosed |
| US-7169795-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-20050096309-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | TFPI, F12, F5 | CYP3A4 656/4885TSHR 1888/4885TDP1 3477/4885 |
| US-20050096309-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | TFPI, F12, F5 | CYP3A4 656/4885TSHR 1888/4885TDP1 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.